Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
CLDX · Why this verdict
Why Celldex Therapeutics (CLDX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock has formed a golden cross, sits above all key moving averages with an RSI of 56 and bullish MACD, and shows sustained volume accumulation — a configuration consistent with continued upward price momentum in the near term. Momentum | Price trends toward the analyst consensus target; RSI holds in the 50–70 range and on-balance volume continues rising over the next two quarters. | →Stable |
| CounterMomentum in early-stage biotechs depends entirely on pipeline catalysts; without a positive clinical or partnership announcement, the entire technical pattern can reverse within days on a single headline. | ||
Analyst consensus implies roughly 61% upside from the current price of $32.12 to a target near $51.78, and a risk/reward ratio of approximately 8.7-to-1 in favor of the buyer is unusually wide for a name of this size. Price targets | Price closes at least half the gap to $51.78 within 12 months; consensus target holds or expands. | →Stable |
| CounterAnalyst price targets for pre-revenue biotechs regularly embed optimistic pipeline assumptions; a single failed trial could trigger a wave of target cuts that erases the apparent upside almost immediately. | ||
Free cash flow is deeply negative as a share of revenue, there is no recognizable competitive moat, and the financial strength score sits near the bottom of the range — characteristics that collectively place business quality well below the floor for a defensible long position. Quality | If the long-term thesis is intact, the company demonstrates improving cash efficiency and achieves at least one moat-building milestone — exclusivity, a licensing agreement, or positive phase data — over 12 months. | →Stable |
| CounterAccelerated spending on clinical development is rational at this stage; elevated cash consumption may reflect deliberate investment ahead of a value-inflecting readout rather than operational failure. | ||
The company has missed consensus EPS estimates in each of its four most recent reported quarters, with an average shortfall of roughly 10%, indicating that spending consistently runs ahead of analyst models. Earnings | To resolve this concern, actual results must come in above estimates in at least two of the next four reporting periods. | →Stable |
| CounterPre-commercial biotechs often invest aggressively ahead of pivotal trials; higher-than-modeled R&D expense during this window may represent rational capital allocation rather than poor execution discipline. | ||
The stock has formed a golden cross, sits above all key moving averages with an RSI of 56 and bullish MACD, and shows sustained volume accumulation — a configuration consistent with continued upward price momentum in the near term.
→StableMomentum
- Expectation
- Price trends toward the analyst consensus target; RSI holds in the 50–70 range and on-balance volume continues rising over the next two quarters.
CounterMomentum in early-stage biotechs depends entirely on pipeline catalysts; without a positive clinical or partnership announcement, the entire technical pattern can reverse within days on a single headline.
Analyst consensus implies roughly 61% upside from the current price of $32.12 to a target near $51.78, and a risk/reward ratio of approximately 8.7-to-1 in favor of the buyer is unusually wide for a name of this size.
→StablePrice targets
- Expectation
- Price closes at least half the gap to $51.78 within 12 months; consensus target holds or expands.
CounterAnalyst price targets for pre-revenue biotechs regularly embed optimistic pipeline assumptions; a single failed trial could trigger a wave of target cuts that erases the apparent upside almost immediately.
Free cash flow is deeply negative as a share of revenue, there is no recognizable competitive moat, and the financial strength score sits near the bottom of the range — characteristics that collectively place business quality well below the floor for a defensible long position.
→StableQuality
- Expectation
- If the long-term thesis is intact, the company demonstrates improving cash efficiency and achieves at least one moat-building milestone — exclusivity, a licensing agreement, or positive phase data — over 12 months.
CounterAccelerated spending on clinical development is rational at this stage; elevated cash consumption may reflect deliberate investment ahead of a value-inflecting readout rather than operational failure.
The company has missed consensus EPS estimates in each of its four most recent reported quarters, with an average shortfall of roughly 10%, indicating that spending consistently runs ahead of analyst models.
→StableEarnings
- Expectation
- To resolve this concern, actual results must come in above estimates in at least two of the next four reporting periods.
CounterPre-commercial biotechs often invest aggressively ahead of pivotal trials; higher-than-modeled R&D expense during this window may represent rational capital allocation rather than poor execution discipline.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Strong technical momentum and an approximately 61% gap to analyst consensus create an asymmetric setup on paper, but four consecutive earnings misses and free cash flow that is deeply negative relative to revenue place business quality well below any investable threshold.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -14598% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 1.2 |
- ▸Overbought (RSI 86)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.6 |
| Price target | 9.5 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 50%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 3.0 |
| growth rank | 0.0 |
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.4 |
| support resistance | 0.7 |
| 52w position | 9.6 |
Risk (lower is worse)
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.5 |
| days to cover | 0.3 |
| volatility | 2.1 |
| put call | 10.0 |
| implied vol | 1.1 |
| beta | 7.6 |
| debt equity | 8.3 |
- ▸High IV: 74%
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/4M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:5.0>=4.5
- ASYMMETRY:2.3>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- MOMENTUM:5.0<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
2.33
Upside
+34.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 7.9, and Growth at 5.0; the weakest are Quality at 1.4, Catalyst at 2.5, and Technical at 3.6. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 2.33 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Bullish Technical Momentum Setup
Trip ifRSI falls below 40 for 2 consecutive weeks.
- P2Wide Analyst Consensus Upside
Trip ifAnalyst consensus price target compresses by more than 20% from its current $51.78 level within 12 months.
- P3Severe Cash Burn No Moat
Trip ifFree cash flow rises above $0 for 2 consecutive reported quarters.
- P4Persistent Earnings Miss Streak
Trip ifEPS surprise exceeds 0% for 2 consecutive quarters.